Guangshengtang announced that GST-HG131, an innovative drug for hepatitis B treatment from Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary, was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. This is the company's second innovative drug to receive breakthrough treatment certification in the field of hepatitis B treatment. GST-HG131 is an oral small molecule HBsAg inhibitor with obvious clinical advantages. However, the development cycle of innovative drugs is long, the investment is large, and the risk is high. There is a risk that the results will fall short of expectations or even clinical research will fail, and there is uncertainty about whether they can be approved in the future.

Guangshengtang announced that GST-HG131, an innovative drug for hepatitis B treatment from Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative drug holding subsidiary, was included in the list of breakthrough treatment varieties by the Drug Evaluation Center of the State Drug Administration. This is the company's second innovative drug to receive breakthrough treatment certification in the field of hepatitis B treatment. GST-HG131 is an oral small molecule HBsAg inhibitor with obvious clinical advantages. However, the development cycle of innovative drugs is long, the investment is large, and the risk is high. There is a risk that the results will fall short of expectations or even clinical research will fail, and there is uncertainty about whether they can be approved in the future.